-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing Bone Biologics (OTC:BBLG) and Allied Healthcare Products (NASDAQ:AHPI)
Reviewing Bone Biologics (OTC:BBLG) and Allied Healthcare Products (NASDAQ:AHPI)
Bone Biologics (OTC:BBLG – Get Rating) and Allied Healthcare Products (NASDAQ:AHPI – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Profitability
This table compares Bone Biologics and Allied Healthcare Products' net margins, return on equity and return on assets.
Get Bone Biologics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Bone Biologics | N/A | 7,587.33% | 7,258.20% |
| Allied Healthcare Products | -19.82% | -70.44% | -31.16% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Bone Biologics and Allied Healthcare Products, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
| Allied Healthcare Products | 0 | 0 | 0 | 0 | N/A |
Risk & Volatility
Bone Biologics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Allied Healthcare Products has a beta of -2.44, meaning that its share price is 344% less volatile than the S&P 500.
Insider and Institutional Ownership
7.6% of Bone Biologics shares are owned by institutional investors. Comparatively, 4.2% of Allied Healthcare Products shares are owned by institutional investors. 5.1% of Allied Healthcare Products shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Bone Biologics and Allied Healthcare Products' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
| Allied Healthcare Products | $27.05 million | 0.16 | -$5.36 million | ($1.34) | -0.82 |
Bone Biologics has higher earnings, but lower revenue than Allied Healthcare Products.
Summary
Bone Biologics beats Allied Healthcare Products on 8 of the 10 factors compared between the two stocks.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
About Allied Healthcare Products
(Get Rating)
Allied Healthcare Products, Inc. engages in manufacturing respiratory products used in the health care industry in hospitals and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. Its product line includes respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
Bone Biologics (OTC:BBLG – Get Rating) and Allied Healthcare Products (NASDAQ:AHPI – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
骨生物(场外交易：BBLG-GET评级)和联合保健品(纳斯达克：AHPI-GET评级)都是小盘医疗公司，但哪种投资更好？我们将根据两家公司的机构持股、分析师建议、风险、盈利能力、收益、估值和股息的实力进行比较。
Profitability
盈利能力
This table compares Bone Biologics and Allied Healthcare Products' net margins, return on equity and return on assets.
此表比较了骨生物和联合医疗保健产品的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Bone Biologics | N/A | 7,587.33% | 7,258.20% |
| Allied Healthcare Products | -19.82% | -70.44% | -31.16% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 骨生物制品 | 不适用 | 7,587.33% | 7,258.20% |
| 联合医疗保健产品 | -19.82% | -70.44% | -31.16% |
Analyst Ratings
分析师评级
This is a summary of recent ratings and recommmendations for Bone Biologics and Allied Healthcare Products, as reported by MarketBeat.
这是MarketBeat报道的骨生物制品和联合医疗保健产品最近的评级和推荐摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
| Allied Healthcare Products | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 骨生物制品 | 0 | 0 | 1 | 0 | 3.00 |
| 联合医疗保健产品 | 0 | 0 | 0 | 0 | 不适用 |
Risk & Volatility
风险与波动性
Bone Biologics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Allied Healthcare Products has a beta of -2.44, meaning that its share price is 344% less volatile than the S&P 500.
Bone Biologics的贝塔系数为0.24，这意味着其股价的波动性比标准普尔500指数低76%。相比之下，联合医疗保健产品的贝塔系数为-2.44，这意味着其股价的波动性比标准普尔500指数低344%。
Insider and Institutional Ownership
内部人与机构持股
7.6% of Bone Biologics shares are owned by institutional investors. Comparatively, 4.2% of Allied Healthcare Products shares are owned by institutional investors. 5.1% of Allied Healthcare Products shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
骨生物公司7.6%的股份由机构投资者持有。相比之下，联合医疗保健产品公司4.2%的股份由机构投资者持有。联合医疗保健产品公司5.1%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一只股票的长期表现将好于大盘。
Earnings & Valuation
收益与估值
This table compares Bone Biologics and Allied Healthcare Products' revenue, earnings per share and valuation.
该表比较了骨生物和联合保健产品的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
| Allied Healthcare Products | $27.05 million | 0.16 | -$5.36 million | ($1.34) | -0.82 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 骨生物制品 | 不适用 | 不适用 | -161万美元 | 不适用 | 不适用 |
| 联合医疗保健产品 | 2705万美元 | 0.16 | -536万元 | ($1.34) | -0.82 |
Bone Biologics has higher earnings, but lower revenue than Allied Healthcare Products.
与联合医疗保健产品相比，骨生物制药的收益更高，但收入更低。
Summary
摘要
Bone Biologics beats Allied Healthcare Products on 8 of the 10 factors compared between the two stocks.
骨生物公司在两只股票的10个因素中有8个超过了联合医疗保健产品公司。
About Bone Biologics
关于骨生物制品
(Get Rating)
(获取评级)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
骨生物公司是一家医疗设备公司，专注于使用重组人蛋白在脊柱融合中进行骨再生。该公司的Nell-1/DBX是一种组合产品，是一种骨刺激重组蛋白，提供对骨再生的靶向特异性控制。该公司正在开发Nell-1/DBX融合器，用于L4-S1一级退行性腰椎间盘疾病骨性成熟患者的脊柱融合手术。该公司的平台技术在脊柱、整形外科、普通整形外科、整形外科、神经外科、介入放射学和运动医学等外科专业中具有增强的应用效果。它与加州大学洛杉矶分校技术开发集团签署了一项许可协议，开发和商业化用于脊柱融合应用的Nell-1。该公司成立于2004年，总部设在马萨诸塞州伯灵顿。
About Allied Healthcare Products
关于联合医疗保健产品
(Get Rating)
(获取评级)
Allied Healthcare Products, Inc. engages in manufacturing respiratory products used in the health care industry in hospitals and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. Its product line includes respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
联合保健产品公司致力于在医院和备用场所生产用于保健行业的呼吸系统产品，包括亚急性保健设施、家庭保健和紧急医疗保健。其产品线包括呼吸护理产品、医疗气体设备和紧急医疗产品。该公司成立于1979年，总部设在密苏里州圣路易斯。
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受骨生物制品日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收骨生物和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧